Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Drug Profile

Nevanimibe - Millendo Therapeutics

Alternative Names: ATR-101

Latest Information Update: 15 Jun 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan
  • Developer Millendo Therapeutics
  • Class Antineoplastics; Methylamines; Phenols; Small molecules; Urea compounds
  • Mechanism of Action Acetyl-CoA C-acetyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cushing syndrome; Congenital adrenal hyperplasia; Adrenocortical carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adrenocortical carcinoma; Congenital adrenal hyperplasia; Cushing syndrome

Most Recent Events

  • 30 Apr 2021 Nevanimibe is no longer licensed to Millendo Therapeutics worldwide
  • 14 Jul 2020 Discontinued - Phase-I for Adrenocortical carcinoma (Late-stage disease) in USA, Germany (PO) due to unfavourable data from an interim analysis of the phase IIb ATR-101-202 trial in Congenital adrenal hyperplasia (NCT03669549)
  • 14 Jul 2020 Discontinued - Phase-II for Congenital adrenal hyperplasia (In the elderly, Treatment-experienced, In adults) in Czech Republic, Israel, France, Brazil, Spain (PO) due to unfavourable data from an interim analysis of the phase IIb ATR-101-202 trial in Congenital adrenal hyperplasia (NCT03669549)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Sunday alerts not delivered

Due to a technical issue, alerts were not delivered on Sunday 27 April. All content from Sunday will be included in the alerts on Monday 28 April.